Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2017

View Archived Issues

Bayer and DKFZ disclose novel AhR antagonists for cancer

New rat model captures characteristics of AKT3 hemimegencephaly

Principia Biopharma begins clinical studies of PRN-1008 in ITP

Novel alphaVbeta3 antagonists show promise for osteoporosis

UMN Pharma returns influenza vaccine program rights to Protein Sciences

Allakos secures series B financing to advance its development programs

New formulation of Oncaspar approved in Europe

X-Chem enters research collaboration with Abilita Bio

reMYND and Novo Nordisk enter license agreement for ReS-39 in diabetes

FDA approves Pfizer's infliximab biosimilar Ixifi

Targeting potassium channel Kv7.2 may improve Dravet syndrome

Glenmark Pharmaceuticals' phase III study of Ryaltris meets primary endpoint

NIH grant supports IBBR's research into the TCR signaling mechanism

Positive first-in-human data for new complement C3 inhibitor AMY-10

Novel mutation in PIGQ gene tied to epileptic encephalopathy

Bristol-Myers Squibb and Ono Pharmaceutical sign license agreement for ONO-4578

JCR reports topline results from phase I/II study of JR-141 in Hunter's syndrome

Meiji and Kaketsuken to enter into memorandum of understanding regarding new company

Novel PD-1 signaling inhibitors presented by Institute of Materia Medica of Beijing

Institute of Materia Medica of Beijing divulges salinomycin oxime ether derivatives

SLC22A12 inhibitors described in Institute of Materia Medica of Beijing patent

Scancell and Cancer Research UK partner to progress SCIB-2 into phase I/II study

Idera Pharmaceuticals patents antisense oligonucleotides for cancer

Vertex enters development agreement with CRISPR Therapeutics for gene-editing treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...